If You Invested $1000 In Insmed Stock 10 Years Ago, You Would Have This Much Today

Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?

Liquidia (LQDA) and Insmed (INSM) are compared as commercial-stage biopharmaceutical companies focused on pulmonary hypertension treatments. LQDA shows impressive commercial momentum with Yutrepia generating $170.4M in Q2 sales and achieving four consecutive profitable quarters, but faces heavy reliance on a single product. INSM offers a more diversified portfolio with Brinsupri's strong launch ($1.25-$1.40B 2026 guidance) and established Arikayce revenue, plus a broader pipeline. While LQDA has outperformed INSM significantly this year (106.9% vs -28.5%), analysts recommend INSM as the more compelling long-term choice due to its diversified revenue base and sustainable growth story.

Insmed Announces Japan's Ministry Of Health, Labour And Welfare Approved BRINSUPRI For Non-Cystic Fibrosis Bronchiectasis In Patients 12 Years And Older

Biotech Is Booming, But These 2 Stocks Missed the Memo

The iShares Biotechnology ETF is trading at new highs and 18 out of its top 20 constituents are green for the year.

JP Morgan Maintains Overweight on Insmed, Lowers Price Target to $175

JP Morgan analyst Jessica Fye maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $179 to $175.